Neuroendocrine liver metastases often require multiple modes of treatment to attain disease control, which can utilize various forms of radiolabelled agents either delivered systemically or preferentially towards the liver. A recent trial suggested both safety and efficacy of a novel approach of combining the two to provide a radiation ‘boost’ to hepatic deposits.
- Andrea Frilling
- Ashley Kieran Clift
